Department of Biotechnology (DBT), along with the Centre for Stem Cell Research (CSCR) develops 1st human gene therapy for Haemophilia A | Current Affairs | Vision IAS
News Today Logo

    Department of Biotechnology (DBT), along with the Centre for Stem Cell Research (CSCR) develops 1st human gene therapy for Haemophilia A

    Posted 12 Dec 2024

    2 min read

    This Gene therapy used a lentiviral vector to introduce a normal copy of the Factor VIII gene into autologous hematopoietic stem cells (HSCs) to treat Haemophilia A (refer to box). 

    • Lentiviral vectors are a type of viral vector that can be used to transfer genetic material.
    • HSCs are multipotent primitive cells that can develop into all types of blood cells.
    Image representing Gene Therapy process

    About Gene therapy 

    • Gene therapy is a technique that uses a gene(s) to treat, prevent or cure a disease or medical disorder.
      • It works by replacing faulty genesdeactivating harmful ones, or introducing new genes to improve or restore health.
      • It uses products/methods such as Plasmid DNA (Genetically engineered Circular DNA molecules), Human gene editing technology, etc. 
    • Types of Gene Therapy
    • Germline gene therapy:  In it, the Germline Cell (egg or sperm) are modified by the introduction of functional genes.
    • Somatic cell gene therapy: In this, therapeutic gene are transferred to a patient’s somatic cells (cells other than germline cells). 
    • Application: both inherited genetic diseases (e.g., sickle cell disease) and acquired disorders (e.g., leukemia) could be treated.

    About Haemophilia

    • It is a rare condition that affects the blood's ability to clot.
    • India bears the world’s second-largest burden of haemophilia. 
    • Haemophilia A is caused by the deficiency of clotting Factor VIII.
    • Tags :
    • Gene Editing
    • Haemophilia A
    • lentiviral vector
    Watch News Today
    Subscribe for Premium Features